Table 2.
Univariate and multivariate analyses of biochemical recurrence-free survival (Cox proportional hazards regression model)
| Variable | Univariate analysis
|
Multivariate analysis
|
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (years) | ||||
| ≥65 vs <65 | 1.063 (0.614–1.838) | 0.828 | ||
| Tumor size (cm) | ||||
| ≥2.5 cm vs <2.5 cm | 1.489 (0.881–2.515) | 0.137 | ||
| Gleason score | ||||
| ≥7 vs <7 | 3.115 (1.622–5.985) | 0.001 | 3.352 (1.665–6.750) | 0.001 |
| Preoperative PSA level | ||||
| ≥10 vs <10 (ng/mL) | 1.497 (0.824–2.720) | 0.185 | ||
| Clinical stage | ||||
| T3–T4 vs T2 | 1.048 (0.581–1.890) | 0.876 | ||
| Lymph node metastasis | ||||
| Positive vs negative | 3.393 (1.720–6.693) | <0.001 | 3.735 (1.801–7.743) | <0.001 |
| Multiple lesions | ||||
| Positive vs negative | 2.788 (1.639–4.744) | <0.001 | 4.109 (2.305–7.325) | <0.001 |
| LOC440040 expression | ||||
| High vs low | 3.625 (2.050–6.412) | <0.001 | 4.871 (2.604–9.110) | <0.001 |
Abbreviations: HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen.